Accuron MedTech, a division of Accuron Technologies Limited, a wholly-owned subsidiary of Temasek Holdings, has led an investment totalling $11.2 million into AWAK Technologies, a Singapore medtech start-up developing solutions that address end-stage renal disease.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
